Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes
Open Access
- 1 November 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Cardiovascular Interventions
- Vol. 8 (11), e002837
- https://doi.org/10.1161/circinterventions.115.002837
Abstract
Background—: The mechanisms underlying pulmonary arterial hypertension (PAH) are multifactorial. The efficacy of pulmonary artery denervation (PADN) for idiopathic PAH treatment has been evaluated. This study aimed to analyze the hemodynamic, functional, and clinical responses to PADN in patients with PAH of different causes. Methods and Results—: Between April 2012 and April 2014, 66 consecutive patients with a resting mean pulmonary arterial pressure ≥25 mm Hg treated with PADN were prospectively followed up. Target drugs were discontinued after the PADN procedure. Hemodynamic response and 6-minute walk distance were repeatedly measured within the 1 year post PADN follow-up. The clinical end point was the occurrence of PAH-related events at the 1-year follow-up. There were no PADN-related complications. Hemodynamic success (defined as the reduction in mean pulmonary arterial pressure by a minimal 10% post PADN) was achieved in 94% of all patients, with a mean absolute reduction in systolic pulmonary arterial pressure and mean pulmonary arterial pressure within 24 hours of −10 mm Hg and −7 mm Hg, respectively. The average increment in 6-minute walk distance after PADN was 94 m. Worse PAH-related events occurred in 10 patients (15%), mostly driven by the worsening of PAH (12%). There were 8 (12%) all-cause deaths, with 6 (9%) PAH-related deaths. Conclusions—: PADN was safe and feasible for the treatment of PAH. The PADN procedure was associated with significant improvements in hemodynamic function, exercise capacity, and cardiac function and with less frequent PAH-related events and death at 1 year after PADN treatment. Further randomized studies are required to confirm the efficacy of PADN for PAH. Clinical Trial Registration—: URL: http://www.chictr.trc.com.cn . Unique identifier: chiCTR-ONC-12002085.Keywords
This publication has 27 references indexed in Scilit:
- Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension: The Single-Center, Prospective, First-in-Man PADN-1 Study (First-in-Man Pulmonary Artery Denervation for Treatment of Pulmonary Artery Hypertension)Journal of the American College of Cardiology, 2013
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2013
- A low resting heart rate at diagnosis predicts favourable long-term outcome in pulmonary arterial and chronic thromboembolic pulmonary hypertension. A prospective observational studyRespiratory Research, 2012
- Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertensionThe Journal of Heart and Lung Transplantation, 2011
- Predicting Survival in Pulmonary Arterial HypertensionCirculation, 2010
- Clinical worsening in trials of pulmonary arterial hypertension: results and implicationsCurrent Opinion in Pulmonary Medicine, 2010
- Tadalafil Therapy for Pulmonary Arterial HypertensionCirculation, 2009
- Clinical Effectiveness of Beta-Blockers in Heart Failure: Findings From the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) RegistryJournal of the American College of Cardiology, 2009
- A meta-analysis of randomized controlled trials in pulmonary arterial hypertensionEuropean Heart Journal, 2008
- Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertensionThe American Journal of Cardiology, 1999